ZEGERID (omeprazole, sodium bicarbonate) by Salix Pharmaceuticals is proton pump inhibitors [moa]. Approved for sodium bicarbonate for oral suspension is indicated in adults for: reduction of risk of upper gastrointestinal (gi) bleeding in critically ill patients ( ). First approved in 2006.
Drug data last refreshed 7h ago · AI intelligence enriched 2d ago
ZEGERID is an oral capsule combining omeprazole (a proton pump inhibitor) with sodium bicarbonate, approved in 2006 for reduction of upper GI bleeding risk in critically ill patients. It works by suppressing gastric acid secretion via inhibition of the proton pump mechanism. The sodium bicarbonate component facilitates rapid omeprazole absorption in the acidic gastric environment.
Approaching loss of exclusivity with minimal Part D volume (1,457 claims in 2023) signals a niche, declining brand with likely workforce optimization underway.
Proton Pump Inhibitors
Proton Pump Inhibitor
Phase III Study Comparing Zegerid® With Losec® for the Relief of Heartburn Associated With Gastroesophageal Reflux Disease
A Study to Compare Omeprazole Administered as Zegerid® Powder and as Prilosec® Capsule in Healthy Participants (P08050)(CL2010-12)
A Three-Period Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions
A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (Study CL2008-02)(P07814)(COMPLETED)
A Pharmacodynamic Study Comparing Zegerid® and Prilosec OTC® (CL2007-17 )(P07813)(COMPLETED)
Worked on ZEGERID at Salix Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on ZEGERID offers limited career growth due to approaching loss of exclusivity and minimal Part D volume (1,457 claims in 2023). Career value lies in managing mature-brand operations, hospital relationships, and cost-containment strategies rather than launch excitement or market expansion.